AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 10 - (NewsRx.com & NewsRx.net) --
by Sonia Nichols, senior medical writer - Patients with malignant mesothelioma might benefit from augmentative therapies combining immunological gene therapy with tumor debulking.
The process of minimizing tumor size appears to allow the transfer of genes encoding for certain immune factors to work better, according to an international cohort of scientists.
Malignant mesothelioma, most often associated with exposure to asbestos, is difficult to treat. However, Sutapa Mukherjee and colleagues at the University of Western Australia and the Harvard School of Public Health have demonstrated that immunological gene therapy is somewhat effective for treating mesothelioma in limited human trials. Tumor debulking, however, has raised the bar on the effectiveness of immunological gene therapy, the group says.
The new research was carried out on mice injected with malignant mesothelioma cells at regions both local and distal to subcutaneous injection sites. Investigators debulked the tumors following their establishment and administered inoculations of syngeneic tumor transfectants encoded for a number of common immune factors in tissues far away from the tumors themselves.
"Neither debulking surgery nor gene therapy alone delayed tumor growth. However, there was a clear delay of tumor growth when debulking surgery was combined with vaccination of tumor transfectants expressing B7-1 or high levels of ...
Source: HighBeam Research, Immunological Gene Therapy And Tumor Debulking Delays Mesothelioma...